Clinical Trial

A Study of Sacituzumab Govitecan in People With Mesothelioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-06-21; most recent amendment 2026-05-26.
Trial Details
NCT Number NCT06477419
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Gilead Sciences
Conditions Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
Enrollment 33 participants
Start Date 2024-06-21
Primary Completion 2029-06-21 (estimated)
Study Completion 2029-06-21 (estimated)
Updated on ClinicalTrials.gov 2026-05-28